{'fraction_non_alphanumeric': 0.05728900255754476, 'fraction_numerical': 0.04092071611253197, 'mean_word_length': 4.78698224852071, 'pattern_counts': {'":': 0, '<': 4, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effects of Low-Dose Fluticasone Propionate/Salmeterol Combination Therapy on Exhaled Nitric Oxide and Nitrite/Nitrate in Breath Condensates from Patients with Mild Persistent Asthma

Objective. The long-acting β2-agonist salmeterol in combination with the corticosteroid fluticasone propionate is used in clinical practice for the treatment of mild persistent asthma. Although the effect of fluticasone propionate alone in asthmatic patients is well documented, the effect of fluticasone propionate/salmeterol (FSC) combination therapy on airway inflammation and airway hyperresponsiveness (AHR) is not well characterized. Thus, we evaluated AHR, exhaled nitric oxide (FENO), and nitrite and nitrate in exhaled breath condensates (EBCs) from mild persistent asthmatic patients treated with a low-dose FSC (100/50). Methods. In this open label study, 18 mild persistent, steroid-naïve asthmatics (age, 22–62 years, forced expiratory volume in 1 s (FEV1) > 70% predicted, provocative dose resulting in 20% reduction (PD20) < 10 mg/mL) were treated with FSC 100/50 for 4 weeks. PD20 to methacholine, FEV1, FENO, and EBC nitrite and nitrate was measured before and after treatment. Results. After 4 weeks of therapy with FSC 100/50, FENO decreased from 74 ppb (SD = 37) to 34 ppb (SD = 15) (p < .001). FEV1 (% predicted) increased from 89.4 (SD = 10.7) to 93.3 (SD = 9.5) (p < .01). The PD20 for methacholine increased from 3.0 (±3.2) to 10.3 (±8.4) mg/mL (p < .01) in 3 of 18 patients reaching the maximum allowable dose (25 mg/mL). FENO correlated with the log of the methacholine dose. There was no statistically significant change in EBC nitrite and nitrate before and after treatment. Conclusions. Treatment of mild persistent, steroid-naïve asthmatics with low-dose combination therapy is effective in rapidly reducing airway inflammation and AHR. Our results suggest different metabolic origins for nitrite, nitrate, and FENO in this group of patients.